Truist Financial analyst assigns Buy rating to Caribou Biosciences with $3.50 price target.

Caribou Biosciences (CRBU) received a Buy rating from Truist Financial analyst Asthika Goonewardene, with a price target of $3.50, representing a 75% upside from current levels. The company has a Moderate Buy analyst consensus and a one-year high of $3.00 and low of $0.66.

Caribou Biosciences, Inc. (CRBU) reported its second-quarter 2025 financial results, with the company's president and CEO, Rachel Haurwitz, PhD, highlighting the progress of its allogeneic CAR-T cell therapies, CB-010 and CB-011, in the treatment of large B cell lymphoma and multiple myeloma, respectively [1].

The company's cash, cash equivalents, and marketable securities stood at $183.9 million as of June 30, 2025, down from $249.4 million at the end of 2024. Caribou expects this funding to support its current operating plan until the second half of 2027 [1].

Caribou's licensing and collaboration revenue decreased to $2.7 million for the three months ended June 30, 2025, from $3.5 million in the same period last year. Research and development expenses were $27.7 million, down from $35.5 million in the previous year, primarily due to strategic pipeline prioritization and related workforce reduction [1].

The company reported a net loss of $54.1 million, or $0.58 per share, basic and diluted, for the second quarter 2025, compared to $37.7 million, or $0.42 per share, in the same period last year. Non-GAAP net loss, excluding non-cash impairment charges, was $32.8 million, or $0.35 per share, basic and diluted [1].

Analysts have responded positively to Caribou Biosciences' progress. Truist Financial analyst Asthika Goonewardene has assigned a Buy rating to the company, with a price target of $3.50, representing a 75% upside from current levels. This rating is in line with the company's Moderate Buy analyst consensus [1].

References:

[1] https://www.nasdaq.com/press-release/caribou-biosciences-reports-second-quarter-2025-financial-results-and-provides